Year’s start mostly strong for biotech IPOs 

With optimism rising that markets will be more receptive to new biotech listings this year than the last two years, the aftermarket performance of the half-dozen companies that have gone public in the U.S. already in 2024 represents an auspicious start.

Among the six biotechs that have priced on NASDAQ or NYSE this year, four finished Friday’s session trading above their IPO prices. The six listings represent twice as many than at this time last year...